THE WIRE · № 59565
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
01 THE MACHINE READ
WHY IT MATTERS.
AI protein design partnership is a private biotech tooling deal, with no listed counterparty exposure.
AI drug-design adoption continues, no public ticker
Preclinical candidate nomination or partnership expansion
Platform output may not yield viable therapies
FULL DISPATCH
Hansa is deploying Cradle's end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease. AMSTERDAM, Oct. 1, 2026 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 20262026-10-01 11:30 UTC
Should You Invest in the First Trust NASDAQ Oil & Gas ETF (FTXN)?2026-10-01 09:20 UTC
AI is operating inside the healthcare billing system. Patients may already be paying the price2026-10-01 11:30 UTC
Meta, ServiceNow and these 7 other tech stocks could lead the next leg of the AI trade2026-10-01 11:54 UTC
Scale Computing, Inc. Announces Fifth Annual SC//Platform™ 2027 Summit in Las Vegas2026-10-01 12:00 UTC
Codoxo Awarded on TIME's List of the World's Top HealthTech Companies 20262026-10-01 12:01 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.